sc13gza
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
TARGACEPT, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
87611R306
(CUSIP Number)
December 31, 2008
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
o Rule 13d-1(c)
þ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting persons initial filing on
this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for
the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to
the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
This Amendment No. 1 amends and supplements the Statement on Schedule 13G electronically filed with
the Securities and Exchange Commission (the Commission) on August 01, 2007 with respect of the
ownership of securities of Targacept, Inc. (the Initial Statement).
The undersigned hereby amends and supplements Items 4 and 6 of Initial Statement with the following
information (capitalized terms used herein without definition shall have the same meaning as set
forth in the Initial Statement).
|
|
|
|
|
|
1 |
|
NAMES OF REPORTING PERSONS . I.R.S. Identification Nos. of above persons (entities
only) GlaxoSmithKline plc
|
|
|
|
|
|
|
2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
(a) o |
|
(b) o |
|
|
|
3 |
|
SEC USE ONLY |
|
|
|
|
|
|
|
4 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
|
England and Wales |
|
|
|
|
|
5 |
|
SOLE VOTING POWER |
|
|
|
NUMBER OF |
|
1,424,176 |
|
|
|
|
SHARES |
6 |
|
SHARED VOTING POWER |
BENEFICIALLY |
|
|
OWNED BY |
|
-0- |
|
|
|
|
EACH |
7 |
|
SOLE DISPOSITIVE POWER |
REPORTING |
|
|
PERSON |
|
1,424,176 |
|
|
|
|
WITH |
8 |
|
SHARED DISPOSITIVE POWER |
|
|
|
|
|
-0- |
|
|
|
9 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
1,424,176 |
|
|
|
10 |
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |
|
|
|
o |
|
|
|
11 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
|
|
|
5.7% |
|
|
|
12 |
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
|
|
|
CO |
2
Item 1.
|
(a) |
|
Name of Issuer |
|
|
|
|
|
|
|
(b) |
|
Address of Issuers Principal Executive Offices |
|
|
|
|
|
Item 2.
|
(a) |
|
Name of Person Filing |
|
|
|
|
|
|
|
(b) |
|
Address of Principal Business Office or, if none, Residence |
|
|
|
|
|
|
|
(c) |
|
Citizenship |
|
|
|
|
|
|
|
(d) |
|
Title of Class of Securities |
|
|
|
|
|
|
|
(e) |
|
CUSIP Number |
|
|
|
|
|
Item 3. Not applicable.
3
Item 4.
Ownership
The information in Items 1 and 5 through 11 on the cover pages (page 2) on Schedule 13G is hereby
incorporated by reference.
Item 5.
Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has
ceased to be the beneficial owner of more than five percent of the class of securities, check the
following o.
Item 6.
Ownership of More than Five Percent on Behalf of Another Person
Shares held by following wholly-owned subsidiaries of Reporting Person:
Glaxo Group Limited 1,096,932
SmithKline Beecham Corporation 327,244
|
|
|
Item 7. |
|
Identification and Classification of the Subsidiary Which Acquired the Security
Being Reported on By the Parent Holding Company |
Item 8. Identification and Classification of Members of the Group
Item 9. Notice of Dissolution of Group
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities
referred to above were acquired and are held in the ordinary course of business and were not
acquired and not held for the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
4
After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
GlaxoSmithKline plc
|
|
|
By: |
/s/ Victoria Whyte
|
|
|
|
Victoria Whyte |
|
|
|
Deputy Company Secretary |
|
|
5